{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:14Z","timestamp":1793502914769,"version":"4.5.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Currently in the UK and Ireland, after a hip fracture most patients do not receive bone protection medication to reduce the risk of refracture. Yet randomised controlled trial data specifically examining patients with hip fracture have shown that intravenous zoledronate reduces refracture risk by a third. Despite this evidence, use of intravenous zoledronate is highly variable following a hip fracture; many hospitals are providing this treatment, whilst most are currently not. A range of clinical uncertainties, doubts over the evidence base and practical concerns are cited as reasons. This paper discusses these concerns and provides guidance from expert consensus, aiming to assist orthogeriatricians, pharmacists and health services managers establish local protocols to deliver this highly clinically and cost-effective treatment to patients before they leave hospital, in order to reduce costly re-fractures in this frail population.<\/jats:p>","DOI":"10.1093\/ageing\/afad172","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T16:44:07Z","timestamp":1692117847000},"source":"Crossref","is-referenced-by-count":40,"title":["Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture"],"prefix":"10.1093","volume":"52","author":[{"given":"Antony","family":"Johansen","sequence":"first","affiliation":[{"name":"Cardiff University University Hospital of Wales and College of Medicine, , Cardiff CF14 4XW , UK"},{"name":"Royal College of Physicians Falls and Fragility Fracture Audit Programme, , London NW1 4LE , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opinder","family":"Sahota","sequence":"additional","affiliation":[{"name":"Nottingham University Hospital Department of Health Care of Older People, , Nottingham NG7 2UH , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Dockery","sequence":"additional","affiliation":[{"name":"Beaumont Hospital , Dublin 9 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J","family":"Black","sequence":"additional","affiliation":[{"name":"NHS Grampian , Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3159-9370","authenticated-orcid":false,"given":"Alasdair M J","family":"MacLullich","sequence":"additional","affiliation":[{"name":"University of Edinburgh Ageing and Health Research Group, , Edinburgh EH9 3EG , UK"},{"name":"Scottish Hip Fracture Audit (SHFA) , Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Kassim","family":"Javaid","sequence":"additional","affiliation":[{"name":"Royal College of Physicians Falls and Fragility Fracture Audit Programme, , London NW1 4LE , UK"},{"name":"University of Oxford Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NDORMS), , Oxford OX3 7HE , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"Ahern","sequence":"additional","affiliation":[{"name":"Cork University Hospital and University College Cork , Cork , Ireland"},{"name":"Health Service Executive , Dublin 8D08 W2A8 , Ireland"},{"name":"Irish Hip Fracture Database (IHFD) , National Office of Clinical Audit, Dublin 2, D02 VN51 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia L","family":"Gregson","sequence":"additional","affiliation":[{"name":"University of Bristol Musculoskeletal Research Unit, Bristol Medical School, , Bristol BS10 5NB , UK"},{"name":"Royal United Hospital NHS Trust Older Persons Unit, , Combe Park, Bath BA1 3NG , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"2024012316464280200_ref1","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac044","article-title":"New national osteoporosis guidance\u2014implications for geriatricians","volume":"51","author":"Gregson","year":"2022","journal-title":"Age Ageing"},{"key":"2024012316464280200_ref2","volume-title":"15 years of quality improvement: the 2023 National Hip Fracture Database report on 2022","author":"Royal College of Physicians"},{"key":"2024012316464280200_ref3","first-page":"58","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","author":"Gregson","year":"2022"},{"key":"2024012316464280200_ref4","article-title":"Clinical guideline for the prevention and treatment of osteoporosis","author":"The National Osteoporosis Guideline Group. NOGG"},{"key":"2024012316464280200_ref5","author":"Scottish Standards of Care for Hip Fracture","year":"2023"},{"key":"2024012316464280200_ref6","article-title":"National Report","author":"Irish Hip Fracture Database (IHFD)","year":"2020"},{"key":"2024012316464280200_ref7","author":"Fracture Liaison Service Database (FLSDB)"},{"key":"2024012316464280200_ref8","author":"The Global Fragility Fracture Network (FFN)"},{"key":"2024012316464280200_ref9","article-title":"Vitamin D deficiency in adults: vitamin D supplements","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"2024012316464280200_ref10","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.2010.594","article-title":"Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial","volume":"303","author":"Sanders","year":"2010","journal-title":"JAMA"},{"key":"2024012316464280200_ref11","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/rheumatology\/kem240","article-title":"Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Smith","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2024012316464280200_ref12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12891-016-1174-9","article-title":"An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial","volume":"17","author":"Mak","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"2024012316464280200_ref13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4158\/EP13265.RA","article-title":"Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review","volume":"20","author":"Kearns","year":"2014","journal-title":"Endocr Pract"},{"key":"2024012316464280200_ref14","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"2024012316464280200_ref15","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1111\/bcp.13332","article-title":"Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study","volume":"83","author":"Cipriani","journal-title":"Br J Clin Pharmacol"},{"key":"2024012316464280200_ref16","article-title":"Prescribing medicines in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactions","author":"MHRA","year":"2019"},{"key":"2024012316464280200_ref17","article-title":"The impact of renal impairment on withdrawal of direct oral anticoagulants in patients with hip fracture","author":"Johansen","journal-title":"Fragility Fracture Network (FFN) Global Congress"},{"key":"2024012316464280200_ref18","article-title":"Intravenous zoledronic acid: adverse effects on renal function","author":"Medicine and Healthcare products Regulatory Agency (MHRA) Drug Safety Update","year":"2017"},{"key":"2024012316464280200_ref19","volume-title":"British National Formulary"},{"key":"2024012316464280200_ref20","volume-title":"Electronic Medicines Compendium"},{"key":"2024012316464280200_ref21","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s00198-022-06499-4","article-title":"Renal safety of zoledronic acid for osteoporosis in adults 75 years and older","volume":"33","author":"Fixen","year":"2022","journal-title":"Osteoporos Int"},{"key":"2024012316464280200_ref22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-021-06160-6","article-title":"Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis","volume":"33","author":"Schini","year":"2022","journal-title":"Osteoporos Int"},{"key":"2024012316464280200_ref23","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00198-022-06427-6","article-title":"Safety of zoledronate in older patients at high risk of fracture with reduced renal function","volume":"33","author":"Sahota","year":"2022","journal-title":"Osteoporos Int"},{"key":"2024012316464280200_ref24","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"2024012316464280200_ref25","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2024012316464280200_ref26","volume-title":"The Renal Drug Handbook"},{"key":"2024012316464280200_ref27","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American association of oral and maxillofacial surgeons position paper on medication related osteonecrosis of the jaw 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"2024012316464280200_ref28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","article-title":"Bisphosphonate-related osteonecrosis of the jaw-a review","volume":"48","author":"Kuhl","year":"2012","journal-title":"Oral Oncol"},{"key":"2024012316464280200_ref29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1524-4741.2011.01119.x","article-title":"Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects","volume":"17","author":"Quispe","year":"2011","journal-title":"Breast J"},{"key":"2024012316464280200_ref30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of jaw: a systematic review and international consensus","volume":"30","author":"Khann","year":"2015","journal-title":"JBMR"},{"key":"2024012316464280200_ref31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00198-012-2042-6","article-title":"Defining the epidemiology of bisphosphonate \u2013associated osteonecrosis of jaw: prior work and current challenges","volume":"24","author":"Solomon","year":"2013","journal-title":"Osteoporos Int"},{"key":"2024012316464280200_ref32","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","article-title":"The incidence of osteonecrosis of jaw in patients\u2019 receiving 5 mg of Zoledronic acid, data from health outcomes and reduced incidence with Zoledronic acid once yearly clinical trials program","volume":"141","author":"Grbic","year":"2010","journal-title":"J Am Dent Assoc"},{"key":"2024012316464280200_ref33","volume-title":"Medication-Related Osteonecrosis of the Jaw","author":"Scottish Dental Clinical Effectiveness Programme"},{"key":"2024012316464280200_ref34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","article-title":"Risk of subsequent fracture after prior fracture among older women","volume":"30","author":"Balasubramanian","year":"2019","journal-title":"Osteoporos Int"},{"key":"2024012316464280200_ref35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12891-021-04051-9","article-title":"Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada","volume":"22","author":"Adachi","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"2024012316464280200_ref36","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/jbmr.1605","article-title":"Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Research"},{"key":"2024012316464280200_ref37","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","article-title":"The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533 ng\/ml","volume":"23","author":"Carmel","year":"2012","journal-title":"Osteoporosis Int"},{"key":"2024012316464280200_ref38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116298","article-title":"Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery","volume":"155","author":"Kashii","year":"2022","journal-title":"Bone"},{"key":"2024012316464280200_ref39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00198-014-2903-2","article-title":"Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Li","year":"2015","journal-title":"Osteoporos Int"},{"key":"2024012316464280200_ref40","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1111\/ans.17792","article-title":"Early bisphosphonate therapy post proximal femoral fracture fixation does not impact fracture healing: a systematic review and meta-analysis","volume":"92","author":"Tong","year":"2022","journal-title":"ANZ J Surg"},{"key":"2024012316464280200_ref41","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1503\/cmaj.161207","article-title":"Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial","volume":"189","author":"Grey","year":"2017","journal-title":"CMAJ"},{"key":"2024012316464280200_ref42","volume-title":"Evidence Based Recommendations on the Bisphosphonates for Treating Technology Appraisal Guidance (TA464)","author":"National Institute for Health and Care Excellence (NICE)","year":"2019"},{"key":"2024012316464280200_ref43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00774-016-0806-3","article-title":"Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis","volume":"35","author":"Shiraki","year":"2017","journal-title":"J Bone Miner Metab"},{"key":"2024012316464280200_ref44","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1359\/jbmr.090209","article-title":"Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture","volume":"24","author":"Eriksen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2024012316464280200_ref45","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose Zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2024012316464280200_ref46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.4453","article-title":"Bone mineral density and bone turnover 10 years after a single 5 mg dose or two 5-yearly lower doses of Zoledronate in Osteopenic older women: an open-label extension of a randomized controlled trial","volume":"37","author":"Grey","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2024012316464280200_ref47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2012-2868","article-title":"Reduction in the risk of clinical fractures after a single dose of Zoledronic acid 5 milligrams","volume":"98","author":"Reid","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012316464280200_ref48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2024012316464280200_ref49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12877-020-01801-7","article-title":"A scoping review of the clinical frailty scale","volume":"20","author":"Church","year":"2020","journal-title":"BMC Geriatr"},{"key":"2024012316464280200_ref50","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with Zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"key":"2024012316464280200_ref51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ejhpharm-2015-000742","article-title":"Setting up a homecare service for zoledronic acid treatment of osteoporosis","volume":"23","author":"Wong","year":"2016","journal-title":"Eur J Hosp Pharm"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/52\/9\/afad172\/56335358\/afad172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/52\/9\/afad172\/56335358\/afad172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T11:52:10Z","timestamp":1706010730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afad172\/7275533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afad172","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,9,1]]},"article-number":"afad172"}}